Literature DB >> 365538

Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline.

S Vandel, B Vandel, M Sandoz, G Allers, P Bechtel, R Volmat.   

Abstract

Plasma levels of amitriptyline and nortriptyline were measured twice weekly in 62 patients treated for three weeks with i.m. amitriptyline 120 mg/day. In half the patients the ratio of amitriptyline to nortriptyline was under 1 and in the other half it was greater than 1. 30 of these 62 patients were clinically monitored with the Hamilton Rating Scale and the side effects of the drug were recorded. There was no correlation between plasma level of the drug and its side effects, but there was a statistically significant curvilinear correlation between the plasma levels of amitriptyline plus nortriptyline and nortriptyline alone, and the clinical effect. The practical value of this type of investigation was demonstrated by showing that patients whose drug plasma level was not in the therapeutic range, were clinically improved after adjustment of the dose. The plasma level of amitriptyline plus nortriptyline must lie between 60 to 220 ng/ml, and that of nortriptyline between 60 to 140 ng/ml, to obtain the best clinical effect. Associated treatments, age, weight and sex of patients, and the type of depression did not appear significantly to affect the plasma level of the drug.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 365538     DOI: 10.1007/bf02089958

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  [Determination of the plasma concentration and antidepressive effect of amitriptyline].

Authors:  R Volmat; P Bechtel; G Allers; B Vandel; S Vandel
Journal:  Therapie       Date:  1977 May-Jun       Impact factor: 2.070

2.  Validity of the Hamilton Rating Scale for depression.

Authors:  J W Knesevich; J T Biggs; P J Clayton; V E Ziegler
Journal:  Br J Psychiatry       Date:  1977-07       Impact factor: 9.319

3.  Plasma nortriptyline and clinical response.

Authors:  G Burrows; B A Scoggins; L R Turecek; B Davies
Journal:  Clin Pharmacol Ther       Date:  1974-10       Impact factor: 6.875

4.  Plasma nortriptyline levels--relationship to clinical effects.

Authors:  M Asberg
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

5.  Plasma-nortriptyline levels in endogenous depression.

Authors:  P Kragh-Sørensen; M Asberg; C Eggert-Hansen
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

6.  Amitriptyline plasma levels and clinical response in primary depression.

Authors:  D J Kupfer; I Hanin; D G Spiker; T Grau; P Coble
Journal:  Clin Pharmacol Ther       Date:  1977-12       Impact factor: 6.875

7.  Amitriptyline plasma levels and therapeutic response.

Authors:  V E Ziegler; B T Co; J R Taylor; P J Clayton; J T Biggs
Journal:  Clin Pharmacol Ther       Date:  1976-06       Impact factor: 6.875

8.  Plasma levels and antidepressive effect of imipramine.

Authors:  L F Gram; N Reisby; I Ibsen; A Nagy; S J Dencker; P Bech; G O Petersen; J Christiansen
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

9.  [Plasma levels of imipramine and desmethylimipramine and antidepressant effect during controlled therapy(author's transl)].

Authors:  R Oliver-Marti n; E Buschsenschultz; P Pichot; J Boissier
Journal:  Psychopharmacologia       Date:  1975

10.  Self-inhibiting action of nortriptylin's antidepressive effect at high plasma levels: a randomized double-blind study controlled by plasma concentrations in patients with endogenous depression.

Authors:  P Kragh-Sorensen; C E Hansen; P C Baastrup; E F Hvidberg
Journal:  Psychopharmacologia       Date:  1976-02-02
View more
  21 in total

Review 1.  Therapeutic drug monitoring of psychotropic medications.

Authors:  P B Mitchell
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

2.  Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression.

Authors:  Sven Ulrich; Jürgen Läuter
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Tricyclic antidepressant plasma level monitoring: intraindividual variability in everyday practice.

Authors:  S Vandel; G Bertschy; S Nezeloff; B Bonin; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Amitriptyline plasma concentration and clinical response.

Authors:  T R Norman; G D Burrows; K P Maguire; B Scoggins
Journal:  Br Med J       Date:  1979-03-31

Review 5.  Discrepancies between pharmacokinetic studies of amitriptyline.

Authors:  P Schulz; P Dick; T F Blaschke; L Hollister
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

6.  Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant; G Garrone
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 7.  Current antidepressant drugs: their clinical use.

Authors:  L E Hollister
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

8.  Biotransformation of amitriptyline in alcoholic depressive patients.

Authors:  M Sandoz; S Vandel; B Vandel; B Bonin; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Metabolism of amitriptyline in patients with chronic renal failure.

Authors:  M Sandoz; S Vandel; B Vandel; B Bonin; B Hory; Y St Hillier; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response.

Authors:  B Vandel; S Vandel; J M Jounet; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.